8-K: Paragon 28 Appoints Dave Demski to Board of Directors, Expanding Board to Nine Members

Paragon 28 has appointed Dave Demski, a seasoned medical device executive, as an independent director, increasing the board size to nine members.

Summary

• Paragon 28 has appointed Dave Demski as an independent director, effective immediately.
• This appointment increases the size of the Board of Directors from eight to nine members.
• Mr. Demski brings over two decades of executive leadership experience in the orthopedic industry.
• He previously served as President and CEO of Globus Medical from August 2017 to April 2022.
• Mr. Demski has also served on the boards of Alphatec Spine and Axonics, Inc.
• He will receive compensation as a non-employee director according to the company's existing program.

Sentiment

Score: 7

Explanation: The appointment of an experienced director is generally viewed positively, suggesting a stable and growth-oriented outlook for the company.

Positives

• The appointment of Dave Demski brings significant industry expertise and leadership experience to the board.
• Mr. Demski's experience at Globus Medical, including his tenure as CEO, is expected to be valuable to Paragon 28.
• The expansion of the board to nine members may enhance strategic oversight and governance capabilities.

Risks

• The document includes forward-looking statements which are subject to risks and uncertainties.
• Actual results could differ materially from those anticipated in the forward-looking statements.

Future Outlook

The company's future success is tied to its ability to improve foot and ankle patient outcomes, and the appointment of Mr. Demski is expected to contribute to this goal.

Management Comments

• Albert DaCosta, Chairman and CEO of Paragon 28, stated that Dave Demski's industry knowledge and leadership experience will be invaluable to the company.
• Dave Demski said he is honored to join the Board of Directors and contribute to the company's mission.

Industry Context

The appointment of a seasoned executive like Dave Demski, with experience at Globus Medical, a major player in the orthopedic industry, suggests Paragon 28 is aiming to strengthen its position in the foot and ankle market.

Comparison to Industry Standards

• The appointment of a former CEO of a major medical device company like Globus Medical is a common practice for companies looking to enhance their strategic direction and governance.
• Dave Demski's experience on the boards of Alphatec Spine and Axonics, Inc. is comparable to other experienced directors in the medical device industry.
• The expansion of the board to nine members is within the typical range for publicly traded companies of this size.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may view the appointment of an experienced director positively.
• Employees may benefit from the enhanced leadership and strategic direction.
• Customers may see improved products and services due to the company's strengthened position.

Key Dates

Keywords

Paragon 28, Board of Directors, Dave Demski, Independent Director, Orthopedic, Medical Device, Corporate Governance, Globus Medical, Alphatec Spine, Axonics